Products - Headaches | Topic | NICE

Showing 8 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Atogepant for preventing migraine (TA973)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Rimegepant for treating migraine (TA919)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 October 2023
Rimegepant for preventing migraine (TA906)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2023
Eptinezumab for preventing migraine (TA871)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 March 2023
Fremanezumab for preventing migraine (TA764)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Erenumab for preventing migraine (TA682)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 March 2021
Galcanezumab for preventing migraine (TA659)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012